Study Of The Relationship Between The Expression Of ERCC1 Gene In The Patients With Non-small Cell Lung Cancer And Effects On Its Prognosis

ObjectiveTo explore the expression of ERCC1 gene in the patients with non-small cell lung cancer and its its influencing factors,annalyze the relationship between the expression of ERCC1 gene in the patients with non-small cell lung cancer and its clincal prognosis and guide cisplatin based chemotherapy clincal value ,as to provide important theoretical evidence for individualized treatment.Methods1. The total number of non-small cell lung cancer samples were collected according its pathology number. The expression of ERCC1 protein of 44 taget samples of non-snall cell lung cancer were determined through immunohistochemical Streptavidin - Peroxidase connection method (S-P method). 44 cases of NSCLC patients with the corresponding routine hematoxylin - eosin staining histological examination.Acoording the level of ERCC1 positive cells staining positive cells and the percentage score f to determine the results.2. Observe the expression of ERCC1 in NSCLC, analyze the relationship between the level of ERCC1 expression and its clinicopathological features.Analysis of ERCC1 expression with its features and cisplatin-based chemotherapy regimens .3. Expression differences of ERCC1 and its relationship with the patients survival were analyzed with x2 test,Kaplan—Meier survival curve and COX regression.Results1. There was 43% (19/44) ERCC1 expression positve of the total 44 case of NSCLC patients.There was no relationship between ERCC1 expression levels and the gender, age, smoking index, histological type, clinical stage of the NSCLC patients (all P> 0.05).2. In NSCLC patients, the survial time of ERCC1 expression negative group is longer than the positive group (P=0.007). ERCC1 negative patients,there was no significant difference between different gender, age, pathological type and clinical stage of smoking index. ERCC1 positive patients in the male patients and patients with earlier stages showed slight survival advantage,but in a different age, pathological type and smoking index in patients with no significant difference.3 The survival of ERCC1 negative patients of NSCLC can benefit from cisplatin-based chemotherapy (P=0.047),but patients of ERCC1 positive not(P= 0.252).4.COX model using multiple regression analysis showed that patients with ERCC1 expression and clinal TNM staging and postoperative chemotherapy are independent prognostic factors(P=0.002, P=0.033,P<0.01 ,respectively).Conclusion1. In non-small cell lung cancer,ERCC1 exsist,the positive rate is 43%;There is no significant correlation between its expression and gender, age, pathological type and clinical stage, smoking index .2. In NSCLC patients, ERCC1 expression of the survival benefit of negative and positive expression of the prognosis of patients with poor prognosis than those with negative expression.ERCC1 may be as an indicator for its prognosis.3. ERCC1 negetive patients, the sex, age, pathological type and smoking index have no significant effect on prognosis. When ERCC1 expression was positive, the male patients and earlier clinical stage got slightly survival advantage.4.Expression of ERCC1 negative patients of NSCLC can benefit from cisplatin-based chemotherapy,ERCC1 gene expression can be used as an effective indicator and an guide for the use of DDP in NSCLC.